APA (7th ed.) Citation

Beelen, D. W., Trenschel, R., Stelljes, M., Groth, C., Masszi, T., Reményi, P., . . . Markiewicz, M. (2020). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): A randomised, non-inferiority, phase 3 trial. The lancet. Haematology, 7(1), . https://doi.org/10.1016/S2352-3026(19)30157-7

Chicago Style (17th ed.) Citation

Beelen, Dietrich W., et al. "Treosulfan or Busulfan Plus Fludarabine as Conditioning Treatment Before Allogeneic Haemopoietic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome (MC-FludT.14/L): A Randomised, Non-inferiority, Phase 3 Trial." The Lancet. Haematology 7, no. 1 (2020). https://doi.org/10.1016/S2352-3026(19)30157-7.

MLA (9th ed.) Citation

Beelen, Dietrich W., et al. "Treosulfan or Busulfan Plus Fludarabine as Conditioning Treatment Before Allogeneic Haemopoietic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome (MC-FludT.14/L): A Randomised, Non-inferiority, Phase 3 Trial." The Lancet. Haematology, vol. 7, no. 1, 2020, https://doi.org/10.1016/S2352-3026(19)30157-7.